Literature DB >> 14534355

A region-specific increase in Galphaq and Galpha11 proteins in brains of rats during cocaine withdrawal.

Gonzalo A Carrasco1, Yahong Zhang, Katerina J Damjanoska, Deborah N D'Souza, Francisca Garcia, George Battaglia, Nancy A Muma, Louis D Van de Kar.   

Abstract

Serotonin 2A (5-HT2A) receptor-mediated increases in plasma hormone levels become supersensitive after 42 h of withdrawal from cocaine treatment. The present study investigated which components of the 5-HT2A receptor signaling system are associated with this supersensitivity. Rats were injected daily for 14 days with either saline or cocaine (15 mg/kg i.p.) twice a day or were injected using a "binge" protocol (three injections per day, 1 h apart). Rats were sacrificed 2 or 7 days after the last cocaine injection, and the levels of membrane and cytosol-associated 5-HT2A receptors, Galphaq, Galpha11, regulators of G protein signaling (RGS)4, and RGS7 proteins were assayed in the hypothalamic paraventricular nucleus, amygdala, and frontal cortex using Western blot analysis. Two days of withdrawal from cocaine, administered twice a day or using a binge protocol, produced an increase in membrane-associated Galphaq and Galpha11 proteins in the paraventricular nucleus and the amygdala (but not in the frontal cortex). This effect was reversible after 7 days of withdrawal. The protein levels of the 5-HT2A receptor, Galphaz protein, and RGS4 or RGS7 proteins were not altered by cocaine withdrawal in any of the above-mentioned brain regions. These findings suggest that the supersensitivity of the 5-HT2A receptors, during withdrawal from chronic cocaine, is associated with an increase in membrane-associated Galphaq and Galpha11 proteins and not with changes in the expression of 5-HT2A receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14534355     DOI: 10.1124/jpet.103.056978

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Cocaine-mediated supersensitivity of 5-HT2A receptors in hypothalamic paraventricular nucleus is a withdrawal-induced phenomenon.

Authors:  G A Carrasco; L D Van de Kar; N R Sullivan; M Landry; F Garcia; N A Muma; G Battaglia
Journal:  Neuroscience       Date:  2006-10-19       Impact factor: 3.590

Review 2.  Regulators of G Protein Signaling in Analgesia and Addiction.

Authors:  Farhana Sakloth; Claire Polizu; Feodora Bertherat; Venetia Zachariou
Journal:  Mol Pharmacol       Date:  2020-05-30       Impact factor: 4.436

Review 3.  Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction.

Authors:  Kathryn A Cunningham; Noelle C Anastasio
Journal:  Neuropharmacology       Date:  2013-07-11       Impact factor: 5.250

Review 4.  Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal.

Authors:  Nobue Kitanaka; Junichi Kitanaka; F Scott Hall; Tomohiro Tatsuta; Yoshio Morita; Motohiko Takemura; Xiao-Bing Wang; George R Uhl
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

5.  Cocaine potentiates multiple 5-HT2A receptor signaling pathways and is associated with decreased phosphorylation of 5-HT2A receptors in vivo.

Authors:  Jade M Franklin; Gonzalo A Carrasco
Journal:  J Mol Neurosci       Date:  2014-09-12       Impact factor: 3.444

6.  Amphetamine self-administration attenuates dopamine D2 autoreceptor function.

Authors:  Erin S Calipari; Haiguo Sun; Khalil Eldeeb; Deborah J Luessen; Xin Feng; Allyn C Howlett; Sara R Jones; Rong Chen
Journal:  Neuropsychopharmacology       Date:  2014-02-11       Impact factor: 7.853

7.  Neurobehavioral phenotyping of G(αq) knockout mice reveals impairments in motor functions and spatial working memory without changes in anxiety or behavioral despair.

Authors:  Aliya L Frederick; Tommy P Saborido; Gregg D Stanwood
Journal:  Front Behav Neurosci       Date:  2012-06-19       Impact factor: 3.558

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.